51![R-Gene® 10 Arginine Hydrochloride Injection, USP For Intravenous Use DESCRIPTION Each 100 mL of R-Gene® 10 (Arginine Hydrochloride Injection, USP) for intravenous use contains 10 g of L-Arginine Hydrochloride, USP in W R-Gene® 10 Arginine Hydrochloride Injection, USP For Intravenous Use DESCRIPTION Each 100 mL of R-Gene® 10 (Arginine Hydrochloride Injection, USP) for intravenous use contains 10 g of L-Arginine Hydrochloride, USP in W](https://www.pdfsearch.io/img/8874ff3b13a9c351612f1f86262a7ef5.jpg) | Add to Reading ListSource URL: www.accessdata.fda.govLanguage: English - Date: 2010-01-24 19:47:27
|
---|
52![HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use OMNITROPE® safely and effectively. See full prescribing information for OMNITROPE®. OMNITROPE® (somatropin [rDNA HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use OMNITROPE® safely and effectively. See full prescribing information for OMNITROPE®. OMNITROPE® (somatropin [rDNA](https://www.pdfsearch.io/img/7e413b579e04dcbe46c99a78b981ca79.jpg) | Add to Reading ListSource URL: www.accessdata.fda.govLanguage: English - Date: 2011-04-15 15:56:07
|
---|
53![PV 7175 AMP_v1 1 HIGHLIGHTS OF PRESCRIBING INFORMATION PV 7175 AMP_v1 1 HIGHLIGHTS OF PRESCRIBING INFORMATION](https://www.pdfsearch.io/img/10a1f06e3912058ca33c265a779199fc.jpg) | Add to Reading ListSource URL: www.accessdata.fda.govLanguage: English - Date: 2011-03-29 11:48:05
|
---|
54![NutropinPLR toFDA04[removed], REVISEDbyGNE[removed]Annotated Draft Labeling Text HIGHLIGHTS OF PRESCRIBING INFORMATION NutropinPLR toFDA04[removed], REVISEDbyGNE[removed]Annotated Draft Labeling Text HIGHLIGHTS OF PRESCRIBING INFORMATION](https://www.pdfsearch.io/img/939559b5d09988456af3c001db2e173b.jpg) | Add to Reading ListSource URL: www.accessdata.fda.govLanguage: English - Date: 2012-04-17 11:13:19
|
---|
55![Public Assessment Report for paediatric studies submitted in accordance with Article 46 of Regulation (EC) No1901/2006, as amended Humatrope Public Assessment Report for paediatric studies submitted in accordance with Article 46 of Regulation (EC) No1901/2006, as amended Humatrope](https://www.pdfsearch.io/img/be7595b6072304f8c049339bd26d9ead.jpg) | Add to Reading ListSource URL: www.hma.euLanguage: English - Date: 2012-06-04 08:47:11
|
---|
56![Public Assessment Report for paediatric studies submitted in accordance with Article 46 of Regulation (EC) No1901/2006, as amended Genotropin Public Assessment Report for paediatric studies submitted in accordance with Article 46 of Regulation (EC) No1901/2006, as amended Genotropin](https://www.pdfsearch.io/img/8a28965d5eefd0ad315f472fd96de6be.jpg) | Add to Reading ListSource URL: www.hma.euLanguage: English - Date: 2013-01-24 11:50:47
|
---|
57![Climb National Information Centre for Metabolic Diseases Growth Hormone Deficiency Other names that may be used for this disorder are: • GHD Growth Hormone Deficiency is a condition in which the production of Growth Ho Climb National Information Centre for Metabolic Diseases Growth Hormone Deficiency Other names that may be used for this disorder are: • GHD Growth Hormone Deficiency is a condition in which the production of Growth Ho](https://www.pdfsearch.io/img/f5b48332979eb0ea56ff41cbcf961ab7.jpg) | Add to Reading ListSource URL: www.climb.org.ukLanguage: English - Date: 2014-03-19 09:21:41
|
---|
58![-----------------------WARNINGS AND PRECAUTIONS----------------------- Acute Critical Illness: Potential benefit of treatment continuation should be weighed against the potential risk (5.1). • Prader-Willi syndrome i -----------------------WARNINGS AND PRECAUTIONS----------------------- Acute Critical Illness: Potential benefit of treatment continuation should be weighed against the potential risk (5.1). • Prader-Willi syndrome i](https://www.pdfsearch.io/img/3c14ec09c1c9dc76c2897df34be947ca.jpg) | Add to Reading ListSource URL: www.accessdata.fda.govLanguage: English - Date: 2011-05-18 16:40:37
|
---|
59![STATE OF MICHIGAN DEPARTMENT OF INSURANCE AND FINANCIAL SERVICES Before the Director of Insurance and Financial Services In the matter of: STATE OF MICHIGAN DEPARTMENT OF INSURANCE AND FINANCIAL SERVICES Before the Director of Insurance and Financial Services In the matter of:](https://www.pdfsearch.io/img/51dc3cac1b6b44d274887c31cd056eb1.jpg) | Add to Reading ListSource URL: www.michigan.govLanguage: English - Date: 2014-06-10 17:07:48
|
---|
60![Health Link Healthy living after treatment for childhood cancer Growth Hormone Deficiency Version[removed] Health Link Healthy living after treatment for childhood cancer Growth Hormone Deficiency Version[removed]](https://www.pdfsearch.io/img/5e16cbf51be872624896b0e7296d86bc.jpg) | Add to Reading ListSource URL: www.survivorshipguidelines.orgLanguage: English - Date: 2009-02-19 12:29:39
|
---|